Catalepsy Treatment Global Market Report 2024

The catalepsy treatment market size has grown strongly in recent years. It will grow from $80.96 billion in 2023 to $86.51 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. During the historical period, the growth in catalepsy treatment can be attributed to several factors including economic influences, increased awareness and education about the condition, development in healthcare infrastructure, drug approvals and changes in the regulatory landscape, as well as advancements in medical research focused on catalepsy.

The catalepsy treatment market size is expected to see strong growth in the next few years. It will grow to $113.46 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. Anticipated growth in the upcoming period is expected to stem from various factors, notably increased investment and funding in catalepsy treatment, alignment with global health trends, the impact of patient advocacy and awareness programs, evolving healthcare policy changes, and innovations in drug development. Key trends projected in the forecast period encompass collaborative research initiatives focused on catalepsy, advancements in neurostimulation therapies, changes in the regulatory landscape affecting treatment options, a continued emphasis on patient advocacy and awareness initiatives, as well as the integration of digital health solutions within catalepsy treatment approaches.

The catalepsy treatment market is anticipated to experience growth due to the increasing prevalence of chronic diseases. Chronic conditions, characterized by lasting three months or longer and often progressing over time, impact a significant portion of the global population, particularly the elderly. Catalepsy, associated with toxic or infectious diseases linked to chronic illnesses, is on the rise, necessitating effective treatment. As of September 2022, the World Health Organization reported that approximately 41 million people, accounting for 74% of global deaths, succumb to chronic noncommunicable diseases (NCD) annually. Notably, 77% of NCD deaths occur in low- and middle-income countries. This escalation in chronic diseases is a driving force behind the growth of the catalepsy treatment market.

The increasing prevalence of neurological disorders is poised to contribute to the expansion of the catalepsy treatment market. Neurological disorders, encompassing various medical conditions affecting the nervous system, including the brain, spinal cord, and peripheral nerves, necessitate effective catalepsy treatment to manage symptoms, slow disease progression, enhance quality of life, and prevent or manage complications. According to The European Academy of Neurology, neurological disorders impact 1 in 3 individuals at some point in their lives, emphasizing the significant and widespread nature of these conditions. This growing prevalence of neurological disorders acts as a key driver for the catalepsy treatment market.

Product innovation emerges as a notable trend in the catalepsy treatment market, with major companies prioritizing the development of innovative solutions to enhance their market positions. A case in point is Hikma Pharmaceuticals PLC, a UK-based manufacturer specializing in non-branded generic and in-licensed pharmaceutical products. In July 2021, the company launched Succinylcholine Chloride Injection, a muscle relaxant designed to provide skeletal muscle relaxation for mechanical ventilation or tracheal intubation. This innovative product, featuring a neuromuscular blocking agent, aims to facilitate the treatment of patients more efficiently and rapidly. This focus on product innovation underscores the commitment of major players to address the evolving needs of the catalepsy treatment market.

Major companies in the catalepsy treatment market are directing their focus towards innovative products, such as baclofen oral granules, to drive revenue growth. Baclofen oral granules represent a specific form of baclofen medication formulated in granular or powder form for oral administration. For example, in June 2022, Amneal Pharmaceuticals, Inc., a US-based pharmaceutical company, introduced lyvispah to the market. Lyvispah is designed to work on spinal cord nerves, reducing the frequency and intensity of muscular spasms in individuals with specific spinal cord-related disorders. This innovative product is a strawberry-flavored, dissolvable granular formulation of baclofen, available in packets containing 5 mg, 10 mg, and 20 mg. It is accessible through specialist and retail channels, providing patients with a convenient and palatable treatment option.

In November 2021, Sanofi S.A., a biopharmaceutical company based in France, executed the acquisition of Kadmon Holdings, Inc. for an undisclosed amount. This strategic acquisition is anticipated to leverage combined resources to strengthen and expand Sanofi's general medicine portfolio. Kadmon Holdings, Inc., a US-based biopharmaceutical company, specializes in the discovery and development of transformative therapies to address unmet medical needs. This acquisition reflects Sanofi's commitment to enhancing its capabilities and offerings in the catalepsy treatment market, aligning with its focus on rare diseases and long-term chronic conditions.

Major companies operating in the catalepsy treatment market report are Upsher-Smith Laboratories LLC, Piramal Enterprises Ltd., Vintage Labs Private Limited, Hikma Pharmaceuticals plc, CASI Pharmaceuticals Inc., Covis Pharma GmbH, GSK plc, Bayer AG, Novartis AG, Aleva Neurotherapeutics SA, Sanofi S.A., Takeda Pharmaceutical Company Limited, Roche Holding AG, Abbott Laboratories, Pfizer Inc., Johnson & Johnson Services Inc., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Eisai Co. Ltd., Glenmark Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Biogen Inc., Amgen Inc., AstraZeneca plc, GlaxoSmithKline plc, Novo Nordisk A/S, Boehringer Ingelheim International GmbH.

North America was the largest region in the catalepsy treatment market in 2023. The regions covered in the catalepsy treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the catalepsy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of catalepsy treatment include drugs, psychotherapy, and other therapeutic interventions. Drugs encompass various substances used to diagnose, treat, or alleviate symptoms of the condition. These medications are administered through oral, parenteral, and alternative routes, and are commonly utilized in hospitals, specialized clinics, and various other healthcare facilities catering to patients with catalepsy.

The catalepsy treatment market research report is one of a series of new reports that provides catalepsy treatment market statistics, including catalepsy treatment industry global market size, regional shares, competitors with a catalepsy treatment market share, detailed catalepsy treatment market segments, market trends and opportunities, and any further data you may need to thrive in the catalepsy treatment industry. This catalepsy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.